biomarker panel for early detection in uterine cancer: a review

Uterine cancer is the numerous prevalent cancers of the female reproductive tract in industrialized as well as developing countries and its probability is arising annually. there is a total of approximated 90,000 mortality and 382,000 instances newly cases treated annually globally. the desire to create and define biological markers for the initial stages detection and therapy of uterine cancer is growing. we analyze the current state of biomarker utilization for early detection, including their sensitivity and specificity, paving the way for timely interventions. several biomarkers, including p53, k-ras, ca-125, her2/neu, he4, pten, msi are used for early detection, treatment, and prevention of uterine cancer. prognostic biomarkers in uterine cancer have emerged as indispensable tools for predicting disease progression and patient outcomes. endometrial biopsy, ct scan, mri scan, dilation and curettage, transvaginal ultrasound are vital for diagnosing and staging of uterine cancer and provide essential information about the cancer’s presence, size, and spread, guiding proper treatment decisions. various treatments modalities, including surgery, chemotherapy, targeted therapies are examined. in conclusion, early detection through biomarkers like p53, k-ras, her2/neu, pten, serum ca-125 holds great promise for early diagnosis and treatment advancements, as well as providing hope for better results and a higher standard of living for individuals in future generations.